Osteoporosis in primary biliary cirrhosis

Panminerva Medica

Volumn 44, Issue 4, 2002, Pages 335-341

  Newton, J ^a   Jones, D ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Liver cirrhosis, biliary; Osteoporosis, diagnosis; Osteoporosis, therapy

Indexed keywords

BILIARY CIRRHOSIS; BONE DISEASE; HUMAN; LIVER TRANSPLANTATION; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

BONE DISEASES; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; OSTEOPOROSIS; RISK FACTORS;

EID: 0036886556     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Neuberger JM. Primary biliary cirrhosis. Lancet 1997;350:875-9.
2. Prince MI, Jones DEJ. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J 2000;76:199-206.
3. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973;289:674-8.
4. Newton JL, Jones DEJ, Metcalf JV, Park JB, Burt AD, Bassendine MF et al. The presentation and mortality of primary biliary cirrhosis in older patients. Age Ageing 2000;29:305-9.
5. Jones DEJ. Autoantigens in primary biliary cirrhosis. J Clin Path 2000;53:1-8.
6. Metcalf JV, Bhopal RS, Gray J, James OFW. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle-upon-Tyne, England. Int J Epidemiol 1997;26:830-6.
7. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107-10.
8. Sutcliffe AM, Francis RM. Osteoporosis: treatment options in elderly patients. Prescriber 1998;9:91-4.
9. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. report of a WHO study group. Geneva: World Health Organisation, 1994.
10. Atkinson M, Nordin BEC, Sherlock S. Bone disease in obstructive jaundice. Q J Med 1956;25:299-312.
11. Kehayoglou AK, Holdsworth CD, Agnew JE, Whelton MJ, Sherlock S. Bone disease and calcium absorption in primary biliary cirrosis with special reference to vitamin-D therapy. Lancet 1968;1(7545):715-8.
12. Guanabens N, Pares A, Marasino L, Brancos A, Piera C, Serrano S et al. Factors influencing the development of metabolic bone disease in primary bilary cirrhosis. Am J Gastroenterol 1990;85:1356-62.
13. Hodgson SF, Rolland-Dickson E, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985;103:855-60.
14. Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982;83:97-102.
15. Janes CH, Rolland-Dickson E, Okazaki R, Bonde S, McDonagh AF, Lawrence-Riggs B. Role of hyperbilirubinaemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995;95:2581-6.
16. Almdal T, Schaadt O, Veaterdal-Jorgensen J, Lindgreen P, Ranek L. Vitamin D, parathyroid hormone and bone mineral content of lumbar spine and femir in primary biliary cirrhosis. J Int Med 1989;225:207-13.
17. Springer JE, Cole DEC, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000;118:145-51.
18. Narayanan Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001;35:316-23.
19. Newton JL, Francis R, Prince M, James OFW, Bassendine MF, Rawlings D et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001;49:282-7.
20. Lindenthal B, Leuschner MS, Ackermann H, Happ J, Leuschner UF. Is primary biliary cirrhosis (PBC) in itself a risk factor for osteoporosis? Hepatology 2000;32:168A.
21. Goldblatt J, Taylor PJS, Lipman T, James OFW, Jones DEJ. Prevalence of fatigue in a geographically based primary biliary cirrhosis population: comparison with community controls. Hepatology 2000;32:28A.
22. Kroger H, Tupperainen M, Honkanen R, Alhava E, Saarikoski S. Bone mineral density and risk factors for osteoporosis: a population based study of 1600 perimenopausal women. Calcif Tissue Int 1994;55:1-7.
23. Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OFW. An exploratory population based case-control study of primary biliary cirrhosis. Hepatology 2000;31:1055-60.
24. Morrison NA, Qi JC, Tokita A, Kelly P, Crofts L, Nguyen TV et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-7.
25. Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996;12:1841-9.
26. Pares A, Guanabens N, Alvarez L, De Osaba MJ, Oriola J, Pons F et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001;33:554-60.
27. Pereira SP, Bray GP, Pitt PI, Li F, Miniz C, Williams R. Non-invasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol. Hepatol 1999;11:323-8.
28. Stellon AJ, Davies A, Compston J, Wiliams R. Osteoporosis in chronic cholestatic liver disease. Q J Med 1985;223:783-90.
29. Mitchision HC, Palmer JM, Bassendine MF, Watson AJ, Bassendine MF, Watson AJ et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992;15:336-44.
30. Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996;25:49-57.
31. Prince MI, James OFW, Holland NP, Jones DEJ. Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol 2000;32:368-73.
32. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982;83:103-8.
33. Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D'Angelo A et al. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997;24:239-44.
34. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomised trial. J Hepatol 2000;33:878-82.
35. Pares A, Guanabens N, Ros I, Alvarez L, Pons F, Caballeria L et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Hepatology 1999;30:472A.
36. Olsson R, Mattsson LA, Obrant K, Mellstrom D. Estrogen-progestegen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999;19:188-92.
37. Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF. Cancer risk in primary biliary cirrhosis: a study in Northern England. Gut 1999;45:756-60.
38. Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994;20:633-7.
39. Guanabens N, Pares A, del Rio L, Roca M, Gomez R, Munoz J et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992;15:345-9.
40. Eastell R, Rolland-Dickson E, Hodgson SF, Weisner RH, Porayako MK, Wahner HW et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991;14:296-300.
41. Ninkovic M, Skingle SJ, Bearcroft PW, DBishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first 3 months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000;12:931-5.
42. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Trans Surg 1998;4:404-9.